Bay Colony Advisory Group Inc d b a Bay Colony Advisors Has $276,000 Stock Position in Novo Nordisk A/S $NVO

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 64.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,970 shares of the company’s stock after selling 9,003 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Novo Nordisk A/S were worth $276,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. True Wealth Design LLC increased its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the last quarter. NewSquare Capital LLC boosted its stake in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $37,000. Maseco LLP bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $39,000. Finally, Steigerwald Gordon & Koch Inc. bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. Morgan Stanley reiterated an “underweight” rating and set a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating on the stock. HSBC reissued a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $56.21.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. oral Wegovy rollout broadens commercial reach: Novo has launched its oral GLP‑1 (the “Wegovy Pill”) across a wide pharmacy network, making it the first oral weight‑loss GLP‑1 widely available in the U.S.; that distribution scale supports faster adoption and incremental sales versus an injection‑only offering. Read More.
• Positive Sentiment: Management sees a bigger oral market long term: Novo executives now expect oral GLP‑1 pills to capture over one‑third of the GLP‑1 market by 2030, implying a larger addressable market and more diverse revenue mix than previously modeled. That raises longer‑term revenue potential and reduces single‑product concentration risk. Read More.
• Positive Sentiment: Behavioral/health spillovers bolster product narrative: Research linking GLP‑1 receptor agonists to lower household spending on alcohol and tobacco supports a broader public‑health and societal value story that can aid payer conversations and public acceptance. Read More.
• Neutral Sentiment: Unusual options activity signals trader interest but not direction: Elevated/options flows show speculative positioning or hedging ahead of catalysts (sales data, guidance, regulation); could increase volatility in the short term without indicating a definitive fundamental shift. Read More.
• Neutral Sentiment: Increased analyst and fund attention raises visibility: Coverage from Fundsmith, Zacks and healthcare ETF narratives is driving investor focus on NVO (both positive for liquidity and sentiment but mixed on valuation). Monitor earnings/sales prints and guidance for conviction. Read More.
• Negative Sentiment: Compounded GLP‑1s pose a near‑term demand and pricing risk: CEO Mike Doustdar warned up to ~1.5M U.S. patients may be using compounded (unapproved, cheaper) GLP‑1 alternatives — that substitution can blunt uptake of branded products and pressure pricing if regulators or payers don’t constrain the compounding market. Read More.
• Negative Sentiment: Analyst caution on valuation and execution: Several commentaries urge caution despite investor confidence — potential overextension in the stock, reliance on continued rapid adoption, and execution risk around pharmacy rollout and payer coverage could cap upside. Read More.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $59.83 on Tuesday. The company’s fifty day moving average is $49.87 and its two-hundred day moving average is $55.15. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The firm has a market capitalization of $267.12 billion, a price-to-earnings ratio of 17.39 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.